CL2014001323A1 - Compuestos derivados de 3-fenil-isoquinolin-1(2h)-ona, inhibidores de parp-1; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer. - Google Patents
Compuestos derivados de 3-fenil-isoquinolin-1(2h)-ona, inhibidores de parp-1; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer.Info
- Publication number
- CL2014001323A1 CL2014001323A1 CL2014001323A CL2014001323A CL2014001323A1 CL 2014001323 A1 CL2014001323 A1 CL 2014001323A1 CL 2014001323 A CL2014001323 A CL 2014001323A CL 2014001323 A CL2014001323 A CL 2014001323A CL 2014001323 A1 CL2014001323 A1 CL 2014001323A1
- Authority
- CL
- Chile
- Prior art keywords
- parp
- isoquinolin
- inhibitors
- cancer
- phenyl
- Prior art date
Links
- VZYRBVZOGGKAKY-UHFFFAOYSA-N 3-phenyl-2h-isoquinolin-1-one Chemical compound C=1C2=CC=CC=C2C(O)=NC=1C1=CC=CC=C1 VZYRBVZOGGKAKY-UHFFFAOYSA-N 0.000 title 1
- 101100407073 Caenorhabditis elegans parp-1 gene Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11190687 | 2011-11-25 | ||
| EP12161489 | 2012-03-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014001323A1 true CL2014001323A1 (es) | 2014-09-05 |
Family
ID=47227787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014001323A CL2014001323A1 (es) | 2011-11-25 | 2014-05-20 | Compuestos derivados de 3-fenil-isoquinolin-1(2h)-ona, inhibidores de parp-1; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9422243B2 (enExample) |
| EP (1) | EP2788328B1 (enExample) |
| JP (1) | JP6106182B2 (enExample) |
| KR (1) | KR20140097457A (enExample) |
| CN (1) | CN103946214B (enExample) |
| AU (1) | AU2012342562B2 (enExample) |
| BR (1) | BR112014012031A2 (enExample) |
| CA (1) | CA2856759A1 (enExample) |
| CL (1) | CL2014001323A1 (enExample) |
| EA (1) | EA027800B1 (enExample) |
| ES (1) | ES2676068T3 (enExample) |
| IN (1) | IN2014CN04671A (enExample) |
| MX (1) | MX2014006015A (enExample) |
| WO (1) | WO2013076090A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2696572C2 (ru) | 2012-03-07 | 2019-08-05 | Инститьют Оф Кансер Ресёрч: Ройял Кансер Хоспитал (Зе) | 3-арил-5-замещенные соединения изохинолин-1-она и их терапевтическое применение |
| ES2666729T3 (es) * | 2013-09-11 | 2018-05-07 | Institute Of Cancer Research: Royal Cancer Hospital (The) | Compuestos de isoquinolin-1-ona 3-aril-5-sustituida y su uso terapéutico |
| JP6663350B2 (ja) * | 2014-01-16 | 2020-03-11 | クロヴィス・オンコロジー，インコーポレーテッド | ヘテロ接合性の喪失を示す乳癌または卵巣癌の患者を治療するためのｐａｒｐ阻害剤の使用 |
| WO2017079641A1 (en) | 2015-11-06 | 2017-05-11 | Neurocrine Biosciences, Inc. | N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases |
| TW202134231A (zh) | 2019-12-06 | 2021-09-16 | 美商紐羅克里生物科學有限公司 | 蕈毒受體4拮抗劑及使用方法 |
| CN119317434A (zh) | 2022-06-15 | 2025-01-14 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的组合疗法 |
| WO2024231548A1 (en) | 2023-05-11 | 2024-11-14 | Astrazeneca Ab | Combination of a parp1 inhibitor and a selective estrogen degrader for treating cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60218458T2 (de) | 2001-05-08 | 2007-11-15 | Kudos Pharmaceuticals Ltd. | Isochinolinon derivate als parp inhibitoren |
| JPWO2002094790A1 (ja) | 2001-05-23 | 2004-09-09 | 三菱ウェルファーマ株式会社 | 縮合ヘテロ環化合物およびその医薬用途 |
| NZ537793A (en) * | 2002-07-24 | 2007-05-31 | Kyorin Seiyaku Kk | 4-(substituted aryl)-5-hydroxyisoquinolinone derivative |
| EP2254888B1 (en) * | 2008-02-22 | 2014-12-24 | Msd K.K. | Novel aminopyridine derivatives having aurora a selective inhibitory action |
| TWI499418B (zh) * | 2009-05-21 | 2015-09-11 | Nerviano Medical Sciences Srl | 異喹啉－１（２ｈ）－酮衍生物 |
-
2012
- 2012-11-20 CA CA2856759A patent/CA2856759A1/en not_active Abandoned
- 2012-11-20 JP JP2014542801A patent/JP6106182B2/ja active Active
- 2012-11-20 EP EP12791464.6A patent/EP2788328B1/en active Active
- 2012-11-20 BR BR112014012031A patent/BR112014012031A2/pt not_active IP Right Cessation
- 2012-11-20 KR KR1020147017409A patent/KR20140097457A/ko not_active Withdrawn
- 2012-11-20 US US14/358,537 patent/US9422243B2/en active Active
- 2012-11-20 WO PCT/EP2012/073125 patent/WO2013076090A1/en not_active Ceased
- 2012-11-20 CN CN201280057586.4A patent/CN103946214B/zh active Active
- 2012-11-20 EA EA201491026A patent/EA027800B1/ru not_active IP Right Cessation
- 2012-11-20 IN IN4671CHN2014 patent/IN2014CN04671A/en unknown
- 2012-11-20 MX MX2014006015A patent/MX2014006015A/es unknown
- 2012-11-20 ES ES12791464.6T patent/ES2676068T3/es active Active
- 2012-11-20 AU AU2012342562A patent/AU2012342562B2/en not_active Ceased
-
2014
- 2014-05-20 CL CL2014001323A patent/CL2014001323A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2014006015A (es) | 2014-06-04 |
| CN103946214B (zh) | 2016-08-17 |
| IN2014CN04671A (enExample) | 2015-09-18 |
| US20140336192A1 (en) | 2014-11-13 |
| EA027800B1 (ru) | 2017-09-29 |
| KR20140097457A (ko) | 2014-08-06 |
| EA201491026A1 (ru) | 2014-11-28 |
| WO2013076090A1 (en) | 2013-05-30 |
| US9422243B2 (en) | 2016-08-23 |
| HK1200166A1 (en) | 2015-07-31 |
| EP2788328B1 (en) | 2018-01-31 |
| EP2788328A1 (en) | 2014-10-15 |
| JP6106182B2 (ja) | 2017-03-29 |
| CA2856759A1 (en) | 2013-05-30 |
| AU2012342562B2 (en) | 2017-02-23 |
| BR112014012031A2 (pt) | 2017-05-30 |
| AU2012342562A1 (en) | 2014-07-10 |
| JP2014533709A (ja) | 2014-12-15 |
| ES2676068T3 (es) | 2018-07-16 |
| CN103946214A (zh) | 2014-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013000016A1 (es) | Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer. | |
| CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| CL2014001829A1 (es) | Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer. | |
| CL2014001858A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer. | |
| CL2012000772A1 (es) | Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata. | |
| CL2015000711A1 (es) | Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona como inhibidores de notch; composicion farmaceutica y uso en el tratamiento del cancer. | |
| CL2015001655A1 (es) | Compuestos derivados de ftalazin-1(2h)-ona, inhibidores selectivos de la poli(adp-ribosa) polimerasa-1; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer. | |
| CL2014000511A1 (es) | Compuestos derivados de quinazolina, inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7; proceso de preparacion; composiciones farmaceuticas que los contienen y el uso en el tratamiento y/o la prevencion de enfermedades tales como cancer. | |
| CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. | |
| CL2013002125A1 (es) | Compuestos derivados de imidazo[5,1-f][1,2,4]triazinas; composicion farmaceutica; y uso en el tratamiento del deterioro cognitivo asociado con esquizofrenia. | |
| CL2014002726A1 (es) | Compuestos derivados de pirrolopirimidina y purina; composicion farmaceutica; utiles en el tratamiento del cancer (div. sol. 566-14). | |
| CL2012003722A1 (es) | Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida. | |
| CL2012000163A1 (es) | Compuestos derivados de quinazolina o pirido[2,3-d]pirimidina, inhibidores de la autofagia; composicion farmaceutica; y su uso para el tratamiento del cancer, pancreatitis, neurodegeneracion, entre otras. | |
| CL2014002557A1 (es) | Compuestos bicíclicos de pirazinona; procedimiento de preparacion; composicion farmaceutica; kit; y uso en el tratamiento y/o prevencion de enfermedades cardiovasculares, cancer, entre otras. | |
| CL2015001202A1 (es) | Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer. | |
| CL2008001540A1 (es) | Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer. | |
| CL2015001731A1 (es) | Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras. | |
| CL2014001729A1 (es) | Compuestos derivados de tieno (3,2-d) pirimidina, inhibidores de quinasas; composicion farmaceutica; y su uso en la prevencion o tratamiento de una enfermedad relacionada con quinasas como cancer. | |
| CL2012001405A1 (es) | Compuestos derivados de espiroindolinona-pirrolidinas; proceso de obtención; composicion farmaceutica; y uso en el tratamiento o profilaxis del cancer. | |
| PL2731947T3 (pl) | Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II | |
| EP2675469A4 (en) | COMPOSITIONS, DEVICES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER | |
| CL2008001076A1 (es) | Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento del cancer. | |
| CL2013002177A1 (es) | Compuestos derivados de 9h-purinas y 7h-pirrolo[2,3-d]-pirimidinas sustituidas, inhibidores de la pi3k de clase i y/o mtor; su composicon farmaceutica; su combinacion farmaceutica; y su uso en el tratamiento o la prevencion del cancer o trastornos neurodegenerativos. | |
| CL2014000849A1 (es) | Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas. | |
| DK3040336T3 (da) | Forbindelser til brug i behandling af TYK2 Kinase-medierede tilstande |